Company intelligence / Profile preview

Hemispherian

Ownership: Private
Employees: ~4
Development stage: Preclinical

Overview

Lead compound GLIX1 is in late-stage preclinical development for glioblastoma multiforme. The company plans to conduct clinical trials with patients by the end of 2024. Their therapeutics work by restoring a cancer cell's normal epigenetic complement, triggering the DNA damage response and resulting in cancer cytotoxicity.

Therapeutic areas: Oncology
Modalities: Small molecule drugs (GLIX compounds)
Industry: Biotech

Drug pipeline

3 assets

GLIX5

Preclinical

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Hemispherian.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hemispherian.

Explore the full profile